Utah Department of Health & Human Services

STATE OF UTAH
DEPARTMENT OF HEALTH & HUMAN SERVICES
Standing Order for Dispensing COVID-19 At-Home Tests and COVID-19 Home Collection Kits to Utah Medicaid Beneficiaries

I. PURPOSE

Starting January 15, 2022, private health insurance companies are required to cover COVID-19 at-home tests for free to their beneficiaries without a prescription. Utah Medicaid allows payment for Medicaid approved Over-the-Counter products (OTC) if they are prescribed for a beneficiary and listed on the Medicaid approved OTC Product List. To ensure equitable access to COVID-19 at-home tests for Utah Medicaid beneficiaries, Utah will expand access to Food and Drug Administration (FDA) approved and FDA Emergency Use Authorized (EUA) OTC, direct to consumer (DTC), and prescription COVID-19 at-home tests and the OTC, DTC, and prescription COVID-19 home collection kits through a Standing Order for Utah Medicaid beneficiaries.

II. AUTHORIZATION

Pursuant to the authority provided in Utah Code sections §26-1-30 (3) and (6) and §26-6-3, this Standing Order authorizes a pharmacist licensed under the Pharmacy Practice Act Title 58, Chapter 17b of the Utah Code to dispense OTC, DTC, or prescription COVID-19 at-home tests and COVID-19 home collection kits for eligible Utah Medicaid beneficiaries and submit pharmacy claims electronically through the pharmacy point-of-sale system using the National Council of Prescription Drug Plan (NCPDP) version D.0 standard.

III. ELIGIBILITY

Utah Medicaid beneficiaries with proper identification who meet the age requirements of the OTC, DTC, or prescription COVID-19 at-home tests and COVID-19 home collection kits. OTC products on the Medicaid approved OTC Product List are not a benefit through the outpatient pharmacy program for a Medicaid beneficiary who is a resident of a nursing home. The nursing home rate paid by Medicaid to the nursing home includes payment for OTC drugs.

IV. AUTHORIZED TESTS

Pharmacies shall dispense FDA EUA OTC, DTC, and prescription COVID-19 at-home tests and COVID-19 home collection kits listed on the FDA's In Vitro Diagnostics EUA webpage at: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas.

V. INFORMATION TO BE GATHERED FROM INDIVIDUALS REQUESTING COVID-19 AT-HOME TESTS OR COLLECTION KITS

Prior to dispensing a COVID-19 at-home test or COVID-19 home collection kit, the pharmacist shall gather the information below to aid in determining the appropriate test or collection kit to dispense.

A. Patient date of birth
B. Reason for test such as COVID-19 symptoms, COVID-19 exposure, or required for work, school, or travel
C. Date of symptom onset or date of known COVID-19 exposure, as appropriate

VI. INFORMATION TO BE PROVIDED TO INDIVIDUALS RECEIVING AT-HOME COVID-19 TESTS OR COLLECTION KITS

Prior to dispensing the prescription COVID-19 at-home test or COVID-19 home collection kit to the individual, the pharmacist shall provide appropriate educational information to the individual, which shall include, but not be limited to, the following:

A. Written information on home collection kits, including how and when the individual will receive test results.
B. Written information on next steps to take following testing, including information on how to obtain follow-up medical care, and/or to address questions about diagnosis if they test positive for COVID-19.

Utah Department of Health Guidance on COVID-19 at-home tests and COVID-19 home collection kits can be accessed here: https://coronavirus.utah.gov/testing-locations.

VII. TERM

This Standing Order shall take effect immediately. Unless renewed, this Standing Order shall expire 90 days from the date of issuance.

Signed by:

Michelle Hofmann (May 24, 2022 13:30 MDT)

Michelle G. Hofmann, MD, MPH, MHCDS
Dated: April 16, 2022
UT License: 282612-1205; UT CS License: 282612-8905
NPI: 1760550628; DEA: BH8966321